Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

April
26
2018

Sensus Healthcare to Host First Quarter 2018 Financial Results and Business Update Conference Call on May 3, 2018

BOCA RATON, Fla., April 26, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management…

April
19
2018

Sensus Healthcare Expands International Business to Meet Rising Patient Demand for Non-Invasive Skin Cancer and Keloid Treatments

EVP Rick Golin Assumes New Role Bringing Superficial Radio Therapy to International Distributors in Asia, the Americas, Europe and the Middle East BOCA RATON, Fla., April 19, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a…

April
03
2018

Educating Your Patients on Keloid Removal Success Rates

A keloid is a cutaneous mass that characteristically develops following a dermal injury. The keloid has beset dermatologists and cosmetic surgeons for decades, in view of both its pathological evolution and therapeutic challenges. Classically described…

March
27
2018

Tony Perkins: A Keloid Treatment after Removal Success Story in the Making

Tony Perkins is a public school teacher in St. Louis. Mr. Perkins has suffered with keloids on his neck and torso for 15 years. Although keloids are benign growths, the weight of them has caused…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy